1. Home
  2. EXPI vs GERN Comparison

EXPI vs GERN Comparison

Compare EXPI & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo eXp World Holdings Inc.

EXPI

eXp World Holdings Inc.

HOLD

Current Price

$6.76

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.26

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXPI
GERN
Founded
2008
1990
Country
United States
United States
Employees
N/A
258
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
808.3M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
EXPI
GERN
Price
$6.76
$1.26
Analyst Decision
Strong Buy
Hold
Analyst Count
2
3
Target Price
$9.75
$2.17
AVG Volume (30 Days)
1.0M
13.9M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
3.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$500,147,681.00
N/A
Revenue This Year
$6.26
$26.91
Revenue Next Year
$5.50
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
220.39
N/A
52 Week Low
$5.66
$1.04
52 Week High
$12.23
$2.01

Technical Indicators

Market Signals
Indicator
EXPI
GERN
Relative Strength Index (RSI) 60.03 34.40
Support Level $5.68 $1.22
Resistance Level $6.87 $1.29
Average True Range (ATR) 0.23 0.06
MACD 0.04 -0.00
Stochastic Oscillator 81.56 21.15

Price Performance

Historical Comparison
EXPI
GERN

About EXPI eXp World Holdings Inc.

eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: